Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sepracor Lunesta Cancer Risk At Center Of FDA Approvability Debate

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Unusually strict eligibility criteria in the only long-term trial supporting Sepracor’s Lunesta NDA complicated FDA’s analysis of carcinogenicity risk, one of the major issues in the review.

You may also be interested in...



Lunesta Crossover Trial Design, Unblinding By Taste Raised As Review Issues

FDA should re-consider its preference for parallel group rather than crossover trial designs in sleep drug development programs, according to FDA Office of Drug Evaluation I Director Robert Temple, MD

NDA Deficiencies Prolonged Review Of Lunesta Sleep Aid – FDA

Inadequacies in Sepracor's NDA for the insomnia drug Lunesta (eszopiclone) kept FDA from reaching an approval decision during the first review cycle, agency review documents indicate

Lunesta Crossover Trial Design, Unblinding By Taste Raised As Review Issues

FDA should re-consider its preference for parallel group rather than crossover trial designs in sleep drug development programs, according to FDA Office of Drug Evaluation I Director Robert Temple, MD

Related Content

Topics

UsernamePublicRestriction

Register

PS003013

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel